<DOC>
	<DOCNO>NCT00000692</DOCNO>
	<brief_summary>To determine follow use SC-48334 patient AIDS advance AIDS relate complex ( ARC ) : 1 . The large maximum tolerate dose ( MTD ) ; 2 . Effectiveness HIV ; 3 . Pharmacokinetics - fast SC-48334 reach bloodstream , concentration reach , long remain patient 's blood . SC-48334 chemical prevents biochemical action certain enzyme body , recent study show may also prevent activity HIV . The study attempt show whether SC-48334 safely effectively break cycle HIV infection AIDS advance ARC progressively eliminate HIV .</brief_summary>
	<brief_title>Phase I Rising Dose Tolerability Study SC-48334 Patients With Acquired Immunodeficiency Syndrome ( AIDS ) Advanced AIDS Related Complex</brief_title>
	<detailed_description>SC-48334 chemical prevents biochemical action certain enzyme body , recent study show may also prevent activity HIV . The study attempt show whether SC-48334 safely effectively break cycle HIV infection AIDS advance ARC progressively eliminate HIV . Six patient enrol sequentially eight different dose level drug administer mouth least 60 minute meal accord follow schedule : Day 1 : One-quarter total assign daily dose . Patients receive dosage hospital either inpatient outpatient observe 12 hour , time evaluate blood drawn pharmacokinetic study . Patients return 24 48 hour limited physical examination additional pharmacokinetic study . Days 4 - 31 : Total assigned daily dose , one-quarter 4 time day . Patients observe least 5 day hospital follow start part program , time clinical , laboratory , pharmacokinetic information obtain order establish baseline value . After 6th day , patient evaluate complete physical exam , urinalysis , laboratory study week limited physical exam brief laboratory study 3 time week . At eight dose level , second third patient receive first dose first patient follow 72 hour receive first dose . Patients 4 , 5 , 6 begin treatment patient 2 3 complete 14 day four-part total dose . Patients treat outpatient basis , 5 6 day spend hospital evaluation .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>AIDS-Related Complex</mesh_term>
	<mesh_term>Miglustat</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Aerosolized pentamidine . Nystatin . Clotrimazole . Topical acyclovir . Concurrent Treatment : Allowed : Blood transfusion = &gt; grade 3 hemoglobin toxicity . Exclusion Criteria Coexisting Condition : Patients follow condition exclude : Clinical significant diarrhea ( &gt; 3 stool per day &gt; 7 day without definable cause ) . Active opportunistic infection , require ongoing therapy , time enrollment . Any malignancy besides Kaposi 's sarcoma , basal cell carcinoma , squamous cell carcinoma unless squamous cell carcinoma require ongoing therapy . Neurologic disease include dementia , peripheral neuropathy , myelopathy ( CDC category IVb ) . Concurrent Medication : Excluded : Antimetabolites . Alkylating agent . Drugs know hepatic bone marrow toxicity . Patients significant organ dysfunction exclude . Prior Medication : Excluded : Antimetabolites . Alkylating agent . Excluded within 30 day study entry : Any investigational medication . Drugs antiHIV activity . Excluded within 90 day study entry : Ribavirin treatment . Excluded within 6 month study entry : Cancer chemotherapy . Prior Treatment : Excluded within 6 month study entry : Radiation therapy . Patients must demonstrate follow clinical laboratory finding : AIDS advance AIDS relate complex ( ARC ) , accord Centers Disease Control ( CDC ) category IV , exclude neurologic disease IVb . Ability understand term study participation . Current use illicit drug abuse alcohol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Biological Availability</keyword>
	<keyword>1-Deoxynojirimycin</keyword>
</DOC>